Orexo buys US rights to GAIA’s deprexis digital therapeuticSweden’s Orexo has announced it has bought the exclusive US rights to GAIA’s deprexis, a digital therapy to Share XOrexo buys US rights to GAIA’s deprexis digital therapeutichttps://pharmaphorum.com/news/orexo-buys-us-rights-to-gaias-deprexis-digital-therapeutic/
ECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKThe top EU court has endorsed an earlier decision by the UK financial regulator to fine GlaxoSmithKline in Share XECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKhttps://pharmaphorum.com/news/ecj-backs-uk-regulators-pay-for-delay-fine-levied-on-gsk/
NICE rejects J&J’s Spravato for treatment-resistant depressionThe UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal Share XNICE rejects J&J’s Spravato for treatment-resistant depressionhttps://pharmaphorum.com/news/nice-rejects-jjs-spravato-for-treatment-resistant-depression/
Intra-Cellular ends year with OK for schizophrenia drug lumateperoneUS biotech Intra-Cellular Therapies’ has claimed an FDA approval for schizophrenia therapy lumateperone setting up the launch of Share XIntra-Cellular ends year with OK for schizophrenia drug lumateperonehttps://pharmaphorum.com/news/intra-cellular-ends-year-with-ok-for-schizophrenia-drug-lumateperone/
FDA tags psilocybin drug as clinical depression Breakthrough TherapyThe FDA has tagged psilocybin, the illegal psychoactive compound found in ‘magic mushrooms’, as a potential breakthrough treatment Share XFDA tags psilocybin drug as clinical depression Breakthrough Therapyhttps://pharmaphorum.com/news/fda-tags-psilocybin-drug-as-clinical-depression-breakthrough-therapy/
J&J seeks wider use of its Spravato antidepressant in USJohnson & Johnson has filed for US approval for a new claim on the label for its nasal Share XJ&J seeks wider use of its Spravato antidepressant in UShttps://pharmaphorum.com/news/jj-seeks-wider-use-of-its-spravato-antidepressant-in-us/
J&J’s Spravato for depression ‘should be much cheaper’Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer Share XJ&J’s Spravato for depression ‘should be much cheaper’https://pharmaphorum.com/news/jjs-spravato-for-depression-should-be-much-cheaper/
Abilify MyCite and innovating in digital healthpharmaphorum’s Paul Tunnah spoke with Otsuka Pharmaceutical’s North America Pharmaceutical Business president and CEO Kabir Nath about the Share XAbilify MyCite and innovating in digital healthhttps://pharmaphorum.com/views-analysis-digital/abilify-mycite-and-innovating-in-digital-health/
FDA approves Janssen’s ketamine-based nasal antidepressantThe FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment Share XFDA approves Janssen’s ketamine-based nasal antidepressanthttps://pharmaphorum.com/news/fda-approves-janssens-ketamine-based-nasal-antidepressant/
